Cargando…
Nanoparticles Targeting STATs in Cancer Therapy
Over the past decades, an increase in the incidence rate of cancer has been witnessed. Although many efforts have been made to manage and treat this life threatening condition, it is still one of the leading causes of death worldwide. Therefore, scientists have attempted to target molecular signalin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829305/ https://www.ncbi.nlm.nih.gov/pubmed/31569687 http://dx.doi.org/10.3390/cells8101158 |
_version_ | 1783465523592298496 |
---|---|
author | Ashrafizadeh, Milad Ahmadi, Zahra Kotla, Niranjan G. Afshar, Elham Ghasemipour Samarghandian, Saeed Mandegary, Ali Pardakhty, Abbas Mohammadinejad, Reza Sethi, Gautam |
author_facet | Ashrafizadeh, Milad Ahmadi, Zahra Kotla, Niranjan G. Afshar, Elham Ghasemipour Samarghandian, Saeed Mandegary, Ali Pardakhty, Abbas Mohammadinejad, Reza Sethi, Gautam |
author_sort | Ashrafizadeh, Milad |
collection | PubMed |
description | Over the past decades, an increase in the incidence rate of cancer has been witnessed. Although many efforts have been made to manage and treat this life threatening condition, it is still one of the leading causes of death worldwide. Therefore, scientists have attempted to target molecular signaling pathways involved in cancer initiation and metastasis. It has been shown that signal transducers and activator of transcription (STAT) contributes to the progression of cancer cells. This important signaling pathway is associated with a number of biological processes including cell cycle, differentiation, proliferation and apoptosis. It appears that dysregulation of the STAT signaling pathway promotes the migration, viability and malignancy of various tumor cells. Hence, there have been many attempts to target the STAT signaling pathway. However, it seems that currently applied therapeutics may not be able to effectively modulate the STAT signaling pathway and suffer from a variety of drawbacks such as low bioavailability and lack of specific tumor targeting. In the present review, we demonstrate how nanocarriers can be successfully applied for encapsulation of STAT modulators in cancer therapy. |
format | Online Article Text |
id | pubmed-6829305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68293052019-11-18 Nanoparticles Targeting STATs in Cancer Therapy Ashrafizadeh, Milad Ahmadi, Zahra Kotla, Niranjan G. Afshar, Elham Ghasemipour Samarghandian, Saeed Mandegary, Ali Pardakhty, Abbas Mohammadinejad, Reza Sethi, Gautam Cells Review Over the past decades, an increase in the incidence rate of cancer has been witnessed. Although many efforts have been made to manage and treat this life threatening condition, it is still one of the leading causes of death worldwide. Therefore, scientists have attempted to target molecular signaling pathways involved in cancer initiation and metastasis. It has been shown that signal transducers and activator of transcription (STAT) contributes to the progression of cancer cells. This important signaling pathway is associated with a number of biological processes including cell cycle, differentiation, proliferation and apoptosis. It appears that dysregulation of the STAT signaling pathway promotes the migration, viability and malignancy of various tumor cells. Hence, there have been many attempts to target the STAT signaling pathway. However, it seems that currently applied therapeutics may not be able to effectively modulate the STAT signaling pathway and suffer from a variety of drawbacks such as low bioavailability and lack of specific tumor targeting. In the present review, we demonstrate how nanocarriers can be successfully applied for encapsulation of STAT modulators in cancer therapy. MDPI 2019-09-27 /pmc/articles/PMC6829305/ /pubmed/31569687 http://dx.doi.org/10.3390/cells8101158 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ashrafizadeh, Milad Ahmadi, Zahra Kotla, Niranjan G. Afshar, Elham Ghasemipour Samarghandian, Saeed Mandegary, Ali Pardakhty, Abbas Mohammadinejad, Reza Sethi, Gautam Nanoparticles Targeting STATs in Cancer Therapy |
title | Nanoparticles Targeting STATs in Cancer Therapy |
title_full | Nanoparticles Targeting STATs in Cancer Therapy |
title_fullStr | Nanoparticles Targeting STATs in Cancer Therapy |
title_full_unstemmed | Nanoparticles Targeting STATs in Cancer Therapy |
title_short | Nanoparticles Targeting STATs in Cancer Therapy |
title_sort | nanoparticles targeting stats in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829305/ https://www.ncbi.nlm.nih.gov/pubmed/31569687 http://dx.doi.org/10.3390/cells8101158 |
work_keys_str_mv | AT ashrafizadehmilad nanoparticlestargetingstatsincancertherapy AT ahmadizahra nanoparticlestargetingstatsincancertherapy AT kotlaniranjang nanoparticlestargetingstatsincancertherapy AT afsharelhamghasemipour nanoparticlestargetingstatsincancertherapy AT samarghandiansaeed nanoparticlestargetingstatsincancertherapy AT mandegaryali nanoparticlestargetingstatsincancertherapy AT pardakhtyabbas nanoparticlestargetingstatsincancertherapy AT mohammadinejadreza nanoparticlestargetingstatsincancertherapy AT sethigautam nanoparticlestargetingstatsincancertherapy |